Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Council's Chairman of the Board

Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Council's
                            Chairman of the Board

PR Newswire

WASHINGTON, Nov. 2, 2012

WASHINGTON, Nov. 2, 2012 /PRNewswire-USNewswire/ -- The National
Pharmaceutical Council (NPC) today announced that John Gargiulo, President &
CEO, Daiichi Sankyo, Inc., has been elected Chairman of its Board of Directors
for 2012-13. Mr. Gargiulo has served on NPC's Board since 2007, most recently
as Vice Chair.

(Photo:http://photos.prnewswire.com/prnh/20121102/DC05271)

"For many years, John has been committed to fostering NPC's growth as a
leading health care policy research organization," said NPC President Dan
Leonard. "We're looking forward to his leadership as chairman. He brings a
strong track record of accomplishment from Daiichi Sankyo and a keen
understanding of the issues facing our industry and actionable ideas for
change."

"Now more than ever, we need to demonstrate that pharmaceuticals not only
successfully treat and cure disease, but that they can help manage the costs
of health care over time. By managing chronic and preventable diseases with
medicines that have proven to work, we can reduce hospitalizations, and most
of all, help people lead longer and healthier lives," said Mr. Gargiulo. "As
chairman, I'm looking forward to leading NPC as it continues to move forward
on issues related to balancing the needs of patients with the population, the
value of pharmaceuticals, and the use of real-world evidence."

Mr. Gargiulo has more than 25 years of pharmaceutical industry experience. He
has been instrumental in building and shaping the company's U.S. commercial
operations, particularly its cardiovascular business, since its inception in
1996. He has touched nearly every aspect of business operations including
Marketing, Managed Markets and New Product Planning. In the U.S. Daiichi
Sankyo markets therapies in hypertension, dyslipidemia, diabetes, acute
coronary syndrome and metastatic melanoma.

The NPC Board also elected Jeff Huth, Senior Vice President, Managed Markets,
Boehringer Ingelheim Pharmaceuticals, Inc., to serve as its Vice Chair, and
Anne Whitaker, President, North America Pharmaceuticals, Sanofi, as Treasurer.
Rich Fante, President, U.S. Business & Regional Vice President, Americas,
AstraZeneca, is the outgoing chair and will remain active on NPC's Board.

"Under Rich's leadership, NPC took a leap forward as an organization,
becoming a more powerful voice in educating key health care stakeholders about
the development and application of comparative effectiveness research and
other data important to improving health outcomes," said Mr. Leonard.

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization
dedicated to the advancement of good evidence and science, and to fostering an
environment in the United States that supports medical innovation. Founded in
1953 and supported by the nation's major research-based pharmaceutical
companies, NPC focuses on research development, information dissemination, and
education on the critical issues of evidence, innovation and the value of
medicines for patients. For more information, visit www.npcnow.org and follow
NPC on Twitter @npcnow.

SOURCE National Pharmaceutical Council

Website: http://www.npcnow.org
Contact: Andrea Hofelich, ahofelich@npcnow.org, +1-202-827-2078
 
Press spacebar to pause and continue. Press esc to stop.